Do they expect to develop the SubB2M tests for screening after they are approved for monitoring?
Ann: SubB2M/CA15.3 Clinical Validation Data Investor Presentation, page-5
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.035(6.25%) |
Mkt cap ! $65.61M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 59.5¢ | 56.0¢ | $20.62K | 36.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 446 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 30002 | 3 |
View Market Depth
| Last trade - 15.57pm 23/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |